Ribociclib Application Scope

Kisqali® is indicated for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in adult patients. It is used in combination with endocrine therapy, such as an aromatase inhibitor or fulvestrant, to help slow disease progression, improve patient outcomes, and provide a targeted therapy option for those with hormone receptor–positive breast cancer.

Ribociclib Characteristics

Ingredients: Ribociclib
Properties: Oral CDK4/6 inhibitor, targeted therapy for breast cancer
Packaging Specification: 200 mg × 21 tablets/box
Storage: Store in a cool, dry place, away from light
Expiry Date: See packaging
Executive Standard: Drug Registration Regulations
Approval Number: NMPA H20190001
Date of Revision: June 2023
Manufacturer: Novartis

Guidelines for the Use of Kisqali

Dosage and Administration:
- Missed Dose: If a dose is missed, take as soon as possible. Do not double the next dose.
Adverse Reactions:
- Common Adverse Reactions (≥5%):
  - neutropenia, nausea, fatigue, diarrhea
- Serious Adverse Reactions:
  - QT interval prolongation, hepatotoxicity
Contraindications: Patients with known severe hypersensitivity to it or excipients
Precautions:
- Monitor blood counts, liver function, and ECG during treatment
- Advise patients to inform healthcare provider if pregnant, planning pregnancy, or breastfeeding

Ribociclib Interactions

Consult healthcare provider for potential drug interactions

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.